Implementation of Metformin theraPy to Ease Decline of kidney function in Polycystic Kidney Disease (IMPEDE-PKD) Randomised Placebo-Controlled Trial

Research summary

IMPEDE-PKD is a global trial evaluating the long-term efficacy of metformin therapy in slowing the rate of kidney function decline in metformin versus placebo treated Autosomal Dominant Polycystic Kidney Disease (ADPKD) subjects. The UK trial is assessing a primary outcome of change in pain severity from randomisation to 24 months measured using an 11 point numerical rating score (NRS) of average pain over the last 14 days in the ADPKD Pain Assessment Tool (APAT). It is a phase III,international,prospective,multicentre,double-blind,parallel group,placebo-controlled,randomised trial. Secondary outcomes for the global and UK trial are outlined in the trial protocol.

Principal Investigator

Dr Thomas Connor

Contact us

Email: renalandtransplanttrials@ouh.nhs.uk

IRAS number

1010940